" class="no-js "lang="en-US"> Tulane Cancer Center - Medtech Alert
Sunday, September 07, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Tulane Cancer Center | Pharmtech Focus

Tulane Cancer Center

About Tulane Cancer Center

Tulane Cancer Center

A member of the prestigious Association of American Universities, Tulane University is consistently ranked among the top 50 universities in the nation. With research and educational partnerships that span the globe and its location in historic New Orleans, Tulane offers undergraduate, graduate and professional degrees in the liberal arts, science and engineering, architecture, business, law, social work, medicine and public health and tropical medicine.

Related Story

Diseases

 Novartis Pluvicto™ Approved by FDA as First Targeted Radioligand Therapy for Treatment of Progressive

Novartis Pluvicto™ Approved by FDA as First Targeted Radioligand Therapy for Treatment of Progressive, PSMA-positive Metastatic Castration-resistant Prostate Cancer

March 24 2022

Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu […]